Another variety first passed the consistency evaluation

On October 22, Tianshili released an enterprise announcement that its wholly-owned subsidiary Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd (hereinafter referred to as "Jiangsu Diyi") received the supplementary approval document (approval No.: 2019b03973) on the 3mg specification of youzopiclone tablet (trade name "Wenfei", hereinafter referred to as "Wenfei" or "the drug") issued by the State Drug Administration The drugs passed the consistency evaluation of generic drugs Youzopiclone tablet is a new generation of non benzodiazepine sedative hypnotics It is highly selective for GABA receptor, and has the pharmacokinetic characteristics of peak time 1H and half-life 6h It can quickly absorb and induce sleep, maintain complete sleep for 7-8h and slight effect in the next morning In 2012, it was included in the Chinese adult insomnia diagnosis and treatment guide, becoming the first-line treatment drug for insomnia treatment, and successively entered the Chinese insomnia diagnosis and treatment guide, the Chinese expert consensus on the diagnosis and treatment of cardiovascular disease combined with insomnia, the adult obstructive sleep apnea multidisciplinary diagnosis and treatment guide, and the experts on the evaluation and management of sleep disorders of patients with cognitive impairment Consensus "and other guidelines and expert consensus, in many areas of insomnia comorbidity clinical treatment recommendations Right zopiclone has entered the national medical insurance catalogue According to the data of pharmaceutical intelligence, at present, there are three listed enterprises in China: Jiangsu tianshidiyi Pharmaceutical Co., Ltd., Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd and Chengdu Kanghong Pharmaceutical Co., Ltd., but the market share of sample hospitals is occupied by Jiangsu tianshidiyi Pharmaceutical Co., Ltd., accounting for 96.26% In addition, according to the progress database of consistency evaluation of pharmaceutical intelligence data, at present, the consistency evaluation of the three enterprises has been applied for acceptance and completed be In the experiment, Jiangsu Tianshili once again took the lead It was the first one to improve the quality of drugs through consistency evaluation, while further enhancing the competitiveness of products In the current situation that drugs are about to expand the scope of centralized procurement, it is extremely beneficial for its products to further expand market share after the consistency evaluation.